Avidity Biosciences (RNA) announced del-zota topline data from the Phase 1/2 EXPLORE44 trial in people living with Duchenne muscular dystrophy ...
multiple ascending dose Phase 2 trial being conducted in Canada. CONNECT1 has enrolled two cohorts of boys and young men living with DMD amenable to exon 51 skipping and its endpoints include ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback